close

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of novel molecules to promote tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tb4), a 43 amino acid peptide. Its product candidates in clinical development include RGN-137, a topically applied gel for chronic dermal wounds; RGN-259, a sterile topical eye drop for ophthalmic wounds; and RGN-352, a parenteral formulation for the treatment of patients with an acute myocardial infarction, or heart attack. Its pre-clinical development product includes RGN-457, an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases. The company has a strategic partnership with Defiante Farmaceutica L.d.a. for the development and marketing of RGN-137, and certain indications relating to RGN-352 primarily in Europe. RegeneRx Biopharmaceuticals was founded in 1982 and is headquartered in Bethesda, Maryland.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.00
Volume	0
Volume Avg	172600
52 Week High	0.79
52 Week Low	0.22
PE	N/A
PE (group average)	39
EPS Year	0.00
EPS change Q/Q	0%
EPS change Q/Q Yr ago	-33.33%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-125%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%